| Online-Ressource |
Verfasst von: | Breyer, Johannes [VerfasserIn]  |
| Erben, Philipp [VerfasserIn]  |
| Rinaldetti, Sébastien [VerfasserIn]  |
| Worst, Thomas [VerfasserIn]  |
Titel: | FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer |
Verf.angabe: | Johannes Breyer, Ralph M. Wirtz, Philipp Erben, Sebastien Rinaldetti, Thomas S. Worst, Robert Stoehr, Markus Eckstein, Danijel Sikic, Stefan Denzinger, Maximilian Burger, Arndt Hartmann and Wolfgang Otto |
Jahr: | 2019 |
Jahr des Originals: | 2018 |
Umfang: | 10 S. |
Fussnoten: | First published: 18 August 2018 ; Gesehen am 15.08.2019 |
Titel Quelle: | Enthalten in: BJU international |
Ort Quelle: | Oxford : Wiley-Blackwell, 1999 |
Jahr Quelle: | 2019 |
Band/Heft Quelle: | 123(2019), 1, Seite 187-196 |
ISSN Quelle: | 1464-410X |
Abstract: | Objective: To investigate the role of forkhead box protein M1 (FOXM1) mRNA expression and its prognostic value in stage pT1 non-muscle-invasive bladder cancer (NMIBC). Patients and Methods; Clinical data and formalin-fixed paraffin-embedded tissues from transurethral resection of the bladder from patients with stage pT1 NMIBC, treated with an organ-preserving approach, were analysed retrospectively. Total RNA was isolated using commercial RNA extraction kits, and mRNA expression of FOXM1, MKI67, KRT20 and KRT5 was measured by single-step quantitative RT-PCR using RNA-specific TaqMan Assays. Statistical analysis was performed using Spearman's Rho, Wilcoxon or Kruskal–Wallis tests, Kaplan–Meier estimates of recurrence-free (RFS), progression-free (PFS) and cancer-specific survival (CSS) and Cox regression analysis. Results: Data from 296 patients (79.4% men, median age 72 years) were available for the final evaluation. Spearman correlation analysis showed that mRNA expression of FOXM1 was significantly correlated with MKI67 (ρ: 0.6530, P < 0.001) and with the luminal subtype, reflected by the positive correlation with KRT20 (ρ: 0.2113, P < 0.001). Furthermore, there was also a strong correlation of FOXM1 expression with adverse clinical and pathological variables, such as concomitant carcinoma in situ (P = 0.05), multifocal tumours (P = 0.005) and World Health Organization 1973 grade 3 disease (P < 0.001). Kaplan–Meier analysis showed overexpression of FOMX1 to be associated with worse PFS (P = 0.028) and worse CSS (P = 0.015). FOXM1 overexpression was also shown to be a predictive risk factor for CSS (hazard ratio 1.61 [1.13–2.34], L-R chi-squared: 7.19, P = 0.007). FOXM1 overexpression identified a subgroup of patients within the luminal subtype with worse RFS (P = 0.017), PFS (P < 0.001) and CSS (P = 0.015). Patients with low FOXM1 expression had better outcomes, irrespective of instillation therapy, whereas patients with high FOXM1 expression benefitted from intravesical chemotherapy with mitomycin C. Conclusion: High FOXM1 expression was associated with adverse clinical and pathological features and worse outcomes, and predicted response to intravesical instillation therapy in patients with stage pT1 NMIBC. |
DOI: | doi:10.1111/bju.14525 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1111/bju.14525 |
| Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bju.14525 |
| DOI: https://doi.org/10.1111/bju.14525 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | prognosis |
| FOXM1 |
| instillation therapy |
| non-muscle-invasive bladder cancer |
| pT1 |
K10plus-PPN: | 1671475291 |
Verknüpfungen: | → Zeitschrift |
FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer / Breyer, Johannes [VerfasserIn]; 2019 (Online-Ressource)